Asset profile
Trastuzumab Deruxtecan
Antibody–drug conjugate
Approvedregulatory verdict
Evidence outlook
Approved: HR+/HER2- Metastatic Breast Cancer (label: HER2-low and HER2-ultralow metastatic breast cancer, HR-positive or HR-negative, after prior...), Non-Small Cell Lung Cancer
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
129 competitors in this universe: 13 direct rivals (same mechanism and indication), 0 same-class, 116 same-indication.
Unlock with Research ↗
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Trastuzumab Deruxtecan: this drug | Approved | Antibody–drug conjugate | HER2 | ||
| Zanidatamab | Approved | Multispecific antibody | HER2 | ||
| Zongertinib | Approved | Small molecule | HER2, HER2 Mutant-selective | ||
| BL-M07D1 | Phase 3 | Antibody–drug conjugate | HER2 | ||
| DB-1303 | Phase 3 | Monoclonal antibody | HER2 | ||
| Disitamab Vedotin | Phase 3 | Antibody–drug conjugate | HER2 | ||
| Trastuzumab Rezetecan | Phase 3 | Antibody–drug conjugate | HER2 | ||
| Tucatinib | Phase 3 | Small molecule | HER2 | ||
| HRS-4508 | Phase 2 | Small molecule | HER2 | ||
| 177Lu-DWJ155 | Phase 1 | Radiopharmaceutical | HER2 | ||
| BL-M17D1 | Phase 1 | Antibody–drug conjugate | HER2 | ||
| KJ015 | Phase 1 | Monoclonal antibody | HER2 | ||
| MT-304 | Phase 1 | Cell therapy | HER2 | ||
| NVL-330 | Phase 1 | Small molecule | HER2 | ||
| Abemaciclib (Verzenio) | Approved | Small molecule | CDK4 and CDK6 | ||
| Afatinib (Gilotrif) | Approved | Small molecule | EGFR/HER1, HER2, HER4 |
…and 114 more. Research shows the complete landscape.
Research
Unlock with Research ↗Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(103 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (9)
October 2026 (1)
Phase 4HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2026-10-31 · NCT06429761 · CT.gov ↗
What to watch
November 2026 (3)
Phase 2HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2026-11 · NCT06048718 · CT.gov ↗
What to watch
Phase 2Nausea and Vomiting Caused by Trastuzumab DeruxtecanRecruiting
Est. primary completion 2026-11 · NCT07537673 · CT.gov ↗
What to watch
Phase 3Breast Cancer; HER2-positive; MetastaticActive not recruiting
Est. primary completion 2026-11-11 · NCT04784715 · CT.gov ↗
What to watch
December 2026 (5)
Phase 2Non-Small Cell Lung CancerEnrolling by invitation
Est. primary completion 2026-12 · NCT06250777 · CT.gov ↗
What to watch
Phase 3Nausea and Vomiting Caused by Trastuzumab DeruxtecanRecruiting
Est. primary completion 2026-12-06 · NCT07716189 · CT.gov ↗
What to watch
Phase 1HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2026-12-31 · NCT06331169 · CT.gov ↗
What to watch
Phase 1Metastatic Malignant Solid Neoplasm, Platinum-Resistant Ovarian High Grade Serous Adenocarcinoma, Unresectable Malignant Solid NeoplasmRecruiting
Est. primary completion 2026-12-31 · NCT04585958 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2026-12-31 · NCT04553770 · CT.gov ↗
What to watch
2027 (42)
January 2027 (2)
February 2027 (2)
March 2027 (3)
Phase 2Gastric Cancer, HER2-positive Gastric CancerRecruiting
Est. primary completion 2027-03-01 · NCT06253650 · CT.gov ↗
What to watch
Phase 2Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric …Active not recruiting
Est. primary completion 2027-03-23 · NCT04482309 · CT.gov ↗
What to watch
Phase 1Advanced Breast Carcinoma, Advanced Colon Carcinoma, Advanced Colorectal Carcinoma, Advanced Endometrial Carcinoma …Active not recruiting
Est. primary completion 2027-03-31 · NCT04704661 · CT.gov ↗
What to watch
April 2027 (4)
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-04 · NCT06409390 · CT.gov ↗
What to watch
Phase 2HER2-positive Breast CancerActive not recruiting
Est. primary completion 2027-04 · NCT06172127 · CT.gov ↗
What to watch
Phase 4HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-04-27 · NCT05376878 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-04-30 · NCT05900206 · CT.gov ↗
What to watch
May 2027 (3)
Phase 2Colorectal Cancer, Resectable Colorectal CarcinomaRecruiting
Est. primary completion 2027-05 · NCT05845450 · CT.gov ↗
What to watch
Phase 2Gastric CancerActive not recruiting
Est. primary completion 2027-05-04 · NCT04379596 · CT.gov ↗
What to watch
Phase 1/2HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2027-05-28 · NCT04644068 · CT.gov ↗
What to watch
June 2027 (6)
Phase 1Urinary Bladder Neoplasms, Neoplasm Metastasis, Ureteral NeoplasmsRecruiting
Est. primary completion 2027-06 · NCT05614739 · CT.gov ↗
What to watch
Phase 1Gastric Cancer, Gastrointestinal Cancer, HER2 Gene MutationRecruiting
Est. primary completion 2027-06 · NCT05274048 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2027-06-01 · NCT07368543 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-06-01 · NCT06832202 · CT.gov ↗
What to watch
Phase 1/2Locally Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8 …Recruiting
Est. primary completion 2027-06-14 · NCT07012031 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-06-30 · NCT04686305 · CT.gov ↗
What to watch
July 2027 (1)
Phase 1Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 …Recruiting
Est. primary completion 2027-07-08 · NCT06364410 · CT.gov ↗
What to watch
August 2027 (2)
September 2027 (5)
Phase 1/2Advanced Solid Tumor, Homologous Recombination Deficiency, HRR DeficiencyRecruiting
Est. primary completion 2027-09 · NCT06525298 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-09 · NCT07150208 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2027-09-01 · NCT07825753 · CT.gov ↗
What to watch
Phase 2Brain Cancer, Glioblastoma, Metastatic Cancer, Leptomeningeal Metastasis, Recurrent GlioblastomaRecruiting
Est. primary completion 2027-09-22 · NCT06058988 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-09-30 · NCT07393425 · CT.gov ↗
What to watch
October 2027 (4)
Phase 2Prostate Cancer Metastatic, Prostate Cancer, CRPCRecruiting
Est. primary completion 2027-10 · NCT06610825 · CT.gov ↗
What to watch
Phase 2HER2-positive Breast CancerRecruiting
Est. primary completion 2027-10-01 · NCT05982678 · CT.gov ↗
What to watch
Phase 3HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-10-01 · NCT05950945 · CT.gov ↗
What to watch
Phase 2Colorectal Cancer, Colorectal Adenocarcinoma, Rectal Adenocarcinoma, Rectal Cancer, Adenocarcinoma, Rectal Cancer, Metastatic …Recruiting
Est. primary completion 2027-10-20 · NCT07407465 · CT.gov ↗
What to watch
November 2027 (3)
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-11 · NCT07203378 · CT.gov ↗
What to watch
Phase 2Gastroesophageal AdenocarcinomaRecruiting
Est. primary completion 2027-11-09 · NCT07069712 · CT.gov ↗
What to watch
Phase 1Dynamic Tumor Resistance, Metastatic Colorectal CancerNot yet recruiting
Est. primary completion 2027-11-14 · NCT07318389 · CT.gov ↗
What to watch
December 2027 (7)
Phase 2Invasive Breast Cancer, Inflammatory Breast Cancer Stage III, HER2-positive Breast Cancer, HER2 Low Breast Adenocarcinoma, Breast CancerRecruiting
Est. primary completion 2027-12-01 · NCT05795101 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-12-30 · NCT07647016 · CT.gov ↗
What to watch
Phase 1/2Esophagogastric AdenocarcinomaActive not recruiting
Est. primary completion 2027-12-31 · NCT06731803 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-12-31 · NCT07662473 · CT.gov ↗
What to watch
Phase 2Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid TumorsRecruiting
Est. primary completion 2027-12-31 · NCT02693535 · CT.gov ↗
What to watch
Phase 2Desmoplastic Small Round Cell Tumor, Osteosarcoma, Recurrent Desmoplastic Small Round Cell Tumor, Recurrent Kidney Wilms Tumor …Recruiting
Est. primary completion 2027-12-31 · NCT04616560 · CT.gov ↗
What to watch
Phase 4HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2027-12-31 · NCT07162259 · CT.gov ↗
What to watch
2028 (26)
January 2028 (4)
Phase 1/2Solid CancerActive not recruiting
Est. primary completion 2028-01-01 · NCT06771622 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2028-01-01 · NCT06733233 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-01-01 · NCT06533826 · CT.gov ↗
What to watch
Phase 1HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-01-10 · NCT07137416 · CT.gov ↗
What to watch
February 2028 (1)
Phase 1/2Advanced Solid MalignanciesRecruiting
Est. primary completion 2028-02-07 · NCT05417594 · CT.gov ↗
What to watch
March 2028 (2)
Phase 2Gastric Adenocarcinoma, Gastroesophageal Junction AdenocarcinomaActive not recruiting
Est. primary completion 2028-03-31 · NCT05034887 · CT.gov ↗
What to watch
Phase 2Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid NeoplasmRecruiting
Est. primary completion 2028-03-31 · NCT06311214 · CT.gov ↗
What to watch
June 2028 (5)
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-06 · NCT07497386 · CT.gov ↗
What to watch
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-06-01 · NCT07198724 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-06-01 · NCT04986579 · CT.gov ↗
What to watch
Phase 3Gastric Cancer, Gastroesophageal Junction CancerRecruiting
Est. primary completion 2028-06-01 · NCT06731478 · CT.gov ↗
What to watch
Phase 3Biliary Tract CancerRecruiting
Est. primary completion 2028-06-12 · NCT06467357 · CT.gov ↗
What to watch
July 2028 (3)
Phase 2Salivary Gland Carcinoma, Precision TherapyRecruiting
Est. primary completion 2028-07-10 · NCT06145308 · CT.gov ↗
What to watch
Phase 1Metastatic Malignant Solid Neoplasm, Metastatic Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8 …Recruiting
Est. primary completion 2028-07-17 · NCT05372614 · CT.gov ↗
What to watch
Phase 2Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma, Stage III Major Salivary Gland Cancer AJCC v8 …Recruiting
Est. primary completion 2028-07-31 · NCT05408845 · CT.gov ↗
What to watch
August 2028 (1)
Phase 1/2Advanced Solid TumorNot yet recruiting
Est. primary completion 2028-08-12 · NCT07157956 · CT.gov ↗
What to watch
September 2028 (1)
Phase 1/2Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8 …Recruiting
Est. primary completion 2028-09-08 · NCT07619521 · CT.gov ↗
What to watch
October 2028 (2)
November 2028 (3)
Phase 1Advanced Solid TumorActive not recruiting
Est. primary completion 2028-11-01 · NCT06244485 · CT.gov ↗
What to watch
Phase 2HER2 Positive Newly Diagnosed Metastatic Esophageal, Gastric, GEJ Cancer Patients With an ECOG Performance Status of 2Not yet recruiting
Est. primary completion 2028-11-01 · NCT07126561 · CT.gov ↗
What to watch
Phase 3Ovarian CancerRecruiting
Est. primary completion 2028-11-01 · NCT06819007 · CT.gov ↗
What to watch
December 2028 (4)
Phase 1/2T-dxd Resistant HER2-Positive, HER2 Low Metastatic Breast CancerNot yet recruiting
Est. primary completion 2028-12 · NCT07785856 · CT.gov ↗
What to watch
Early phase / not applicableHR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2028-12 · NCT07130344 · CT.gov ↗
What to watch
Phase 1Recurrent or Metastatic Solid TumorsRecruiting
Est. primary completion 2028-12-31 · NCT07015697 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-12-31 · NCT06750484 · CT.gov ↗
What to watch
2029 (11)
January 2029 (2)
February 2029 (1)
Phase 1Breast Cancer, HER2-positive Breast Cancer, Brain Metastases, Cancer, Cancer MetastaticNot yet recruiting
Est. primary completion 2029-02 · NCT07454668 · CT.gov ↗
What to watch
April 2029 (2)
Phase 3Advanced/Metastatic Breast Cancer, HER2+, Low, or Ultralow Advanced/Metastatic Breast CancerRecruiting
Est. primary completion 2029-04-01 · NCT07543536 · CT.gov ↗
What to watch
Phase 3HER2-positive Gastric Cancer, Gastroesophageal Junction AdenocarcinomaRecruiting
Est. primary completion 2029-04-27 · NCT06764875 · CT.gov ↗
What to watch
June 2029 (1)
Phase 2Colorectal Cancer, Adenocarcinoma of the Colon, Adenocarcinoma of the RectumNot yet recruiting
Est. primary completion 2029-06 · NCT07691489 · CT.gov ↗
What to watch
July 2029 (1)
Early phase / not applicableHR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2029-07 · NCT07782086 · CT.gov ↗
What to watch
August 2029 (2)
October 2029 (2)
Phase 2Triple Negative Breast Neoplasms, Neoplasm Metastasis, HER 2 Low-expressing Breast CancerNot yet recruiting
Est. primary completion 2029-10 · NCT07151586 · CT.gov ↗
What to watch
Phase 4HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2029-10 · NCT07195344 · CT.gov ↗
What to watch
2030 (11)
March 2030 (2)
April 2030 (1)
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2030-04-24 · NCT06899126 · CT.gov ↗
What to watch
May 2030 (1)
Phase 1Advanced Solid TumorRecruiting
Est. primary completion 2030-05-15 · NCT05765851 · CT.gov ↗
What to watch
June 2030 (1)
Phase 2HER2-positive Early Breast CancerRecruiting
Est. primary completion 2030-06 · NCT05704829 · CT.gov ↗
What to watch
July 2030 (1)
Phase 3HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2030-07-04 · NCT07683754 · CT.gov ↗
What to watch
September 2030 (1)
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2030-09-30 · NCT03424005 · CT.gov ↗
What to watch
October 2030 (1)
Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2030-10-31 · NCT07619365 · CT.gov ↗
What to watch
December 2030 (3)
Phase 3HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2030-12-20 · NCT07828054 · CT.gov ↗
What to watch
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2030-12-30 · NCT05868226 · CT.gov ↗
What to watch
Phase 1HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2030-12-31 · NCT05633979 · CT.gov ↗
What to watch
2031 (1)
January 2031 (1)
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2031-01-01 · NCT07701941 · CT.gov ↗
What to watch
2032 (2)
March 2032 (1)
Phase 3Endometrial CancerRecruiting
Est. primary completion 2032-03-23 · NCT07022483 · CT.gov ↗
What to watch
May 2032 (1)
Phase 3Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Positive Breast Carcinoma, Oligometastatic Breast CarcinomaNot yet recruiting
Est. primary completion 2032-05-31 · NCT07578116 · CT.gov ↗
What to watch
2036 (1)
March 2036 (1)
Phase 1HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2036-03-30 · NCT07553390 · CT.gov ↗
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.